A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (RECLAIM)
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderate to severe chronic spontaneous urticaria (CSU) inadequately controlled by sgH1-AHs.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study consists of a screening period (up to 4 weeks), a core treatment period (12 weeks double-blind, double-dummy), an optional open-label extension [OLE] period, and safety follow-up period.
Screening period: participants will have a screening period of a minimum of 7 days up to a maximum of 28 days to establish eligibility for the study. Participants meeting all the inclusion criteria and none of the exclusion criteria will be eligible to participate in the study.
Core treatment period (double-blind, double-dummy): approximately, 400 participants diagnosed with CSU inadequately controlled by sgH1-AH will be randomized in this study. Participants will be stratified based on prior exposure to anti-IgE biologics.
Eligible participants will be randomized in a 1:1 ratio to receive remibrutinib and placebo solution for injection or dupilumab and remibrutinib matching placebo, both as an add-on treatment to once daily standard label dose of sgH1-AH background therapy, until the Week 12 visit.
Additionally, all participants will be on a stable, standard label dose of a sgH1-AH ("background therapy") throughout the entire core treatment period (starting a minimum of 7 days prior to randomization until the end of Week 12). To treat unbearable symptoms of CSU, participants will be allowed to add more of the same sgH1-AH on an as-needed basis ("rescue therapy"). The total maximum daily dose of sgH1-AH (background plus rescue) should not exceed 4 tablets/day (4-fold the standard label dose).
Optional open-label extension [OLE] period: At the end of the 12-week double-blind treatment period, and in case remibrutinib is not commercially available, participants from both arms will be given the choice to roll over into an optional OLE safety period and receive remibrutinib (25 mg b.i.d. p.o.) for 12 weeks (up to Week 24).
Safety follow-up period:
- For participants who do not enter the OLE period: there will be a safety follow-up for 12 weeks with safety follow-up phone calls at Week 16 and Week 24 (Week 24 will be end of study).
- For participants who enter the OLE period: there will be 2 options at the end of Week 24:
- If remibrutinib is commercially available: participants will discontinue study treatment, perform their EOT visit and receive a safety follow-up phone call 4 weeks after the last dose of remibrutinib (this will be the EOS).
- If remibrutinib is not commercially available, participants may continue on remibrutinib 25 mg b.i.d. until its commercial availability and return for site visits for safety follow up and treatment dispensation every 3 months. When remibrutinib becomes commercially available, the participant will be contacted for a site visit to complete the EOT visit and will receive a safety follow-up phone call 4 weeks after the last dose of remibrutinib (this will be the EOS).
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Allervie Clinical Research
-
Birmingham, Alabama, United States, 35244
- Cahaba Derm and skin hlth ctr 27
-
-
Arizona
-
Litchfield Park, Arizona, United States, 85340
- Research Solutions of Arizona
-
Payson, Arizona, United States, 85541
- Peak Dermatology
-
Phoenix, Arizona, United States, 85032
- Premier Allergy Asthma And Immunology
-
Scottsdale, Arizona, United States, 85254
- Orso Health
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Acuro Research Inc
-
-
California
-
Fountain Valley, California, United States, 92708
- First OC Dermatology
-
Fremont, California, United States, 95438
- Ctr for Dermatology Clinical Res
-
Huntington Beach, California, United States, 92647
- Allergy and Asthma Specialists Group
-
Long Beach, California, United States, 90808
- Orso Health
-
Long Beach, California, United States, 90815
- Ark Clinical Research
-
Los Angeles, California, United States, 90045
- Dermatology Research Associates
-
Los Angeles, California, United States, 90025
- California Allergy and Asthma Medical Group
-
Napa, California, United States, 94558
- One Of A Kind Clinical Research
-
Palo Alto, California, United States, 94304
- Stanford University Medical Center
-
Pomona, California, United States, 91767
- Empire Clinical Research
-
Redwood City, California, United States, 94063
- Allergy and Asthma Consultants
-
Rocklin, California, United States, 95765
- Norcal Clinical Research
-
Rolling Hills Estates, California, United States, 90274
- Peninsula Research Associates
-
Sacramento, California, United States, 95815
- Integrative Skin Science and Res
-
Sacramento, California, United States, 95817
- UC Davis Neuromuscular Research Center
-
San Diego, California, United States, 92123
- Therapeutics Clinical Research
-
Santa Monica, California, United States, 90403
- Dermatology Institute and Skin Care
-
Upland, California, United States, 91786
- Integrated Research of Inland Inc
-
Walnut Creek, California, United States, 94598
- Allergy and Asthma Clin Res Inc
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital - Aurora
-
Colorado Springs, Colorado, United States, 80909
- Colorado ENT and Allergy
-
Colorado Springs, Colorado, United States, 80907
- Asthma and Allergy Associates P C
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20059
- Howard University Hospital Division of Geriatrics
-
-
Florida
-
Aventura, Florida, United States, 33180
- Florida Ctr Allergy Asthma Research
-
Boca Raton, Florida, United States, 33486
- Skin Care Research Inc
-
Doral, Florida, United States, 33172
- Omnicure Clinical Research
-
Fort Lauderdale, Florida, United States, 33308
- FXM Clinical Research Ft Laud
-
Hollywood, Florida, United States, 33021
- Skin Care Research LLC
-
Jacksonville, Florida, United States, 32216
- Jacksonville Center for Clinical Research
-
Miami, Florida, United States, 33176
- Miami Dade Medical Research
-
Miami, Florida, United States, 33125
- University of MiamiHealth System
-
Miami, Florida, United States, 33175
- FXM Clinical Res Miami LLC
-
Miramar, Florida, United States, 33027
- Eminat LLC
-
North Miami Beach, Florida, United States, 33162
- Ziaderm Research LLC
-
Panama, Florida, United States, 32405
- AllerVie Health
-
Sarasota, Florida, United States, 34233
- Sarasota Clinical Research
-
Sweetwater, Florida, United States, 33172
- Lenus Research and Med Group LLC
-
Tampa, Florida, United States, 33613
- Asthma Allergy Immunology Clin Res
-
Winter Park, Florida, United States, 32789
- Conquest Research
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- AllerVie Clin Res Columbus GA
-
Cumming, Georgia, United States, 30040
- Cleaver Medical Group
-
Douglasville, Georgia, United States, 30135
- Southeast Dermatology Specialists
-
Savannah, Georgia, United States, 31406
- Aeroallergy Research Laboratories
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- The Allergy Group-Meridian Clinic
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60611
- NW Uni C and T Sciences Ins
-
Normal, Illinois, United States, 61761
- Midwest Allergy Sinus Asthma SC
-
O'Fallon, Illinois, United States, 62269
- Clinical Res Ctr of S Illinois
-
River Forest, Illinois, United States, 60305
- Asthma and Allergy Center of Chicago S C
-
Skokie, Illinois, United States, 60077
- Endeavor Health Clinical Trials Center
-
Wheaton, Illinois, United States, 60189
- Accellacare Duly Health and Care
-
-
Indiana
-
Evansville, Indiana, United States, 47715
- Deaconess Clin Allerg Res Inst
-
New Albany, Indiana, United States, 47150
- Southern IN Clinical Trials
-
-
Iowa
-
Ames, Iowa, United States, 50010
- McFarland Clinic PC
-
-
Kentucky
-
Bowling Green, Kentucky, United States, 42104
- Equity Medical LLC
-
Louisville, Kentucky, United States, 40215
- Family Allergy And Asthma Rsch Inst
-
Owensboro, Kentucky, United States, 42301
- Allergy and Asthma Specialist P S C
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70816
- Ochsner Health Center
-
Lafayette, Louisiana, United States, 70508
- Velocity Clinical Research
-
-
Maryland
-
Baltimore, Maryland, United States, 21236
- Chesapeake Clinical Research Inc
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins U School of Med
-
Chevy Chase, Maryland, United States, 20815
- Institute for Asthma and Allergy PC
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Boston Specialists LLC
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106-0525
- ClinSite Inc
-
Caledonia, Michigan, United States, 49316
- Derm Institute West Michigan PLLC
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
Troy, Michigan, United States, 48084
- Somerset Skin Centre
-
Troy, Michigan, United States, 48084
- Revival Research Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Minneapolis, Minnesota, United States, 55402
- Clinical Research Institute
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic - Rochester
-
-
Missouri
-
Columbia, Missouri, United States, 65201
- ENT and Allergy Center of Missouri
-
St Louis, Missouri, United States, 63141
- The Clinical Research Center
-
St Louis, Missouri, United States, 63141
- Washington University
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Somnos Clinical Research
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Las Vegas Dermatology
-
Las Vegas, Nevada, United States, 89128
- Allergy and Asthma Center of Las Vegas
-
-
New Jersey
-
Hamilton, New Jersey, United States, 08619
- Circuit Clinical Mercer Algy Pulm
-
Little Silver, New Jersey, United States, 07739
- Allergy Asthma Assoc Monmouth
-
Ocean Township, New Jersey, United States, 07712
- Allergy Partners of New Jersey PC
-
-
New York
-
The Bronx, New York, United States, 10467
- Montefiore Medical Center
-
The Bronx, New York, United States, 10455
- Equity Medical
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Allergy Partners Of West NC
-
Chapel Hill, North Carolina, United States, 27516
- UNC DermatologyandSkinCancer Ctr
-
-
Ohio
-
Cincinnati, Ohio, United States, 45231
- Bernstein Clinical Research Center
-
Columbus, Ohio, United States, 43213
- CR Services Acquisition US
-
Fairborn, Ohio, United States, 45324
- Wright State University
-
Toledo, Ohio, United States, 43617
- Toledo Institute of Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73118
- Unity Clinical Research
-
Tulsa, Oklahoma, United States, 74136
- Vital Prospects Clinical Research Institute
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Sciences University
-
Portland, Oregon, United States, 97223
- Oregon Medical Research Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, United States, 15241
- Allergy and Clinical Immunology Associates
-
-
South Carolina
-
Greenville, South Carolina, United States, 29607
- Allergic Disease and Asthma Center
-
Greenville, South Carolina, United States, 29601
- Tribe Clinical Research LLC
-
North Charleston, South Carolina, United States, 29420
- National Allergy and Asthma Research LLS
-
North Charleston, South Carolina, United States, 29406
- Charleston ENT and Allergy
-
-
Tennessee
-
Goodlettsville, Tennessee, United States, 37072-2301
- Goodlettsville Dermatology Research
-
Murfreesboro, Tennessee, United States, 37130
- International Clinical Research Tennessee LCC
-
-
Texas
-
Arlington, Texas, United States, 76011
- Arlington Center for Dermatology
-
Austin, Texas, United States, 78759
- Orion Clinical Research
-
Bellaire, Texas, United States, 77401
- Bellaire Dermatology Associates
-
Dallas, Texas, United States, 75230
- Reveal Research Institute
-
Dallas, Texas, United States, 75231
- Pharma Research and Amp Consult
-
El Paso, Texas, United States, 79924
- Western Sky Medical Research
-
Houston, Texas, United States, 77030
- Center for Clinical Studies
-
Kerrville, Texas, United States, 78028
- Sante Clinical Research
-
San Antonio, Texas, United States, 78229
- Andante Research
-
San Antonio, Texas, United States, 78213
- RFSA Dermatology
-
-
Utah
-
Murray, Utah, United States, 84107
- University Of Utah
-
Sandy City, Utah, United States, 84093
- Allergy Associates of Utah
-
-
Virginia
-
Vienna, Virginia, United States, 22182
- Forefront Dermatology
-
-
Washington
-
Bellingham, Washington, United States, 98225
- Bellingham Asthma Allergy and Immunology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults ≥ 18 years of age at the time of signing the informed consent
- CSU duration for ≥ 6 months prior to screening (defined as the onset of CSU determined by the Investigator based on all available supporting documentation)
- Diagnosis of CSU inadequately controlled by sgH1-AH at the time of randomization, defined as:
- The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of sgH1-AH during the 7 days prior to randomization (Day 1):
- UAS7 score (range, 0-42) ≥ 16, and
- ISS7 score (range, 0-21) ≥ 6, and
- HSS7 score (range, 0-21) ≥ 6
- Documentation of hives within 3 months before randomization (either at screening and/or at randomization); or documented in the participants medical history
- Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol
- Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1)
Exclusion Criteria:
- Previous use of remibrutinib or other bruton's tyrosine kinase (BTK) inhibitors
- Previous use of dupilumab
- Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic (past history or current), endocrine or metabolic disorder, or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
- Evidence of hematological disorders (including coagulation disorders or significant bleeding risk)
- History or evidence of gastrointestinal disease (including gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAID), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion)
- Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
- Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants [NOAC])
- History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or hepatic parameters at screening: Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels more than 1.5x ULN or International Normalized Ratio (INR) > 1.5 at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group 1: Remibrutinib + Placebo
Remibrutinib tablet (25 mg b.i.d. p.o.) + placebo solution for injection in pre-filled syringe (2 s.c. injections at baseline and then 1 s.c. injection every other week [Weeks 2-10]) |
Film-coated tablet, oral administration, 25 mg b.i.d. Solution for injection in pre-filled syringe every 2 weeks |
|
Active Comparator: Treatment group 2: Dupilumab + remibrutinib matching placebo
Dupilumab pre-filled syringe (600 mg loading dose [2 x 300 mg dupilumab s.c. injection] at baseline visit followed by dupilumab 300 mg s.c. injection every other week [Weeks 2-10]) + remibrutinib matching placebo tablet (1 tablet b.i.d. p.o.) |
Film-coated tablet, oral administration, b.i.d. Solution for injection in pre-filled syringe 600 mg loading dose followed by 300 mg dose every 2 weeks |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4
Time Frame: Baseline, Week 4
|
The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Baseline, Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score at Week 4
Time Frame: Baseline, Week 4
|
The hives (wheals) severity score, defined by number of hives, will be recorded by the participant twice daily in their eCOA device, on a scale of 0 (none) to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21. |
Baseline, Week 4
|
|
Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score at Week 4
Time Frame: Baseline, Week 4
|
The severity of the itch will be recorded by the participant twice daily in their eCOA device, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21. |
Baseline, Week 4
|
|
Improvement of UAS7, assessed as absolute change from baseline in UAS7 score at Week 1
Time Frame: Baseline, Week 1
|
The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Baseline, Week 1
|
|
Percentage of participants with UAS7 ≤ 6 at Week 4
Time Frame: Week 4
|
Percentage of participants who achieved UAS7 ≤ 6 at Week 4. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 4
|
|
Percentage of participants with UAS7=0 at Week 4
Time Frame: Week 4
|
Percentage of participants who achieved UAS7 = 0 at Week 4. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 4
|
|
Percentage of participants with UAS7 ≤ 6 at Week 2
Time Frame: Week 2
|
Percentage of participants who achieved UAS7 ≤ 6 at Week 2. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 2
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Immune System Diseases
- Hypersensitivity, Immediate
- Hypersensitivity
- Skin Diseases
- Urticaria
- Skin Diseases, Vascular
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Chronic Urticaria
- Therapeutics
- Drug Administration Routes
- Drug Therapy
- Injections
- dupilumab
- remibrutinib
Other Study ID Numbers
Other Study ID Numbers
- CLOU064AUS02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.